Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial

Table 2 Demographic and baseline characteristics

	KGT group (n = 16)	Placebo group (n = 14)	p-value^*
Demographics
Age	70.2 (7.6)	70.1 (6.4)	0.986
Sex (Male)	10 (62.5%)	7 (50%)	0.491
Educational level	12.2 (3.6)	12.3 (4.7)	0.967
Clinical characteristics
SNSB-D	176.00 (24.76)	173.79 (32.86)	0.835
Attention	9.5 (2.3)	9.3 (1.3)	0.783
Language and related function	23.6 (2.3)	22.1 (3.3)	0.232
Visuospatial function	32.94 (2.82)	33.18 (3.05)	0.732
Memory	57.88 (17.76)	57.39 (17.97)	0.942
Frontal/executive function	52.1 (9.2)	51.8 (12.8)	0.946
Other indices
CDR-SB	1.50 (1.00–2.00)	1.50 (0.88–2.50)	0.793
CDR-GS (0.5)	16 (100%)	14 (100%)	–
GDS (3)	16 (100%)	14 (100%)	–
K-MMSE	28.5 (26.3–29.0)	26.0 (24.8–28.3)	0.067
Barthel-ADL	20	20	–
K-IADL	1.0 (1.0–2.0)	1.0 (1.0–1.3)	0.510
SGDS	4.0 (1.3–10.8)	2.5 (1.8–9.0)	0.645

KGT, Kami-guibi-tang; SNSB-D, Seoul Neuropsychological Screening Battery for dementia; CDR-SB, Clinical Dementia Rating-Sum of Boxes; CDR-GS, Clinical Dementia Rating-Global Score; GDS, Global Deterioration Scale; K-MMSE, Korean Mini Mental State Examination; SGDS, Short version-Geriatric Depression Scale; K-IADL, Korean-Instrumental Activities of Daily Living; Barthel-ADL, Barthel-Activities of Daily Living
Values are presented as means (standard deviations), medians (Q1–Q3), or numbers (%)
^*p-values for the between-group comparison using the independent t-test or chi-square test (or Fisher’s exact test)

ISSN: 2662-7671